



23.03.2018

11:30 - 11:45	Welcome and introduction Moderation: A. Bardelli ¹ , J. Tabernero ² ; ¹ Candiolo, (TO)/IT, ² Barcelona, ES	Auditorium
11:30 - 11:45	Welcome to the Symposium	
11:45 - 12:30	Keynote lecture Moderation: A. Bardelli ¹ , J. Tabernero ² ; ¹ Candiolo, (TO)/IT, ² Barcelona, ES	Auditorium
11:45 - 12:05	The cell cycle regulation and biological basis of CDK inhibition <u>J. Endicott</u> , Newcastle Upon Tyne, GB	
13:20 - 14:30	The role of CDK along the mitotic process in normal and pathological condition Moderation: J. Seoane ¹ , N. Turner ² ; ¹ Barcelona, ES, ² London, GB	Auditorium
13:20 - 13:40	Compensation and specificity of function within the CDK family <u>M. Malumbres</u> , Madrid, ES	
13:40 - 14:00	Integration of multiple signalling pathways through control of CDK activation <u>L. Malorni</u> , Prato, IT	
14:00 - 14:20	The biology of the CDK4–CDK6–RB pathway <u>T. Otto</u> , Aachen, DE	
14:20 - 14:30	Q&A	



14:30 - 16:20	The concept of CDK inhibition according to the targeted CDK subtype Moderation: M. Barbacid, Madrid, ES	Auditorium
14:30 - 14:50	CDK 4-6 inhibition <u>M. Arnedos</u> , Villejuif, FR	
14:50 - 15:10	CDK2 as the bypass kinase for CDK4/6 inhibition <u>N. Turner</u> , London, GB	
15:10 - 15:30	The role of CDK4, CDK2 and CDK1 in KRas driven lung tumors: The good, the bad and the ugly <u>M. Barbacid</u> , Madrid, ES	
15:30 - 15:50	DNA damage and checkpoint kinases <u>F. d'Adda di Fagagna</u> , Milan, IT	
15:50 - 16:10	Mechanism of resistance to CDKs inhibitors <u>G. Draetta</u> , Houston, US	
16:10 - 16:20	Q&A	
16:40 - 18:10	Preclinical evidence of efficacy Moderation: G. Curigliano ¹ , F. André ² ; ¹ Milan, IT, ² Villejuif, CEDEX/FR	Auditorium
16:40 - 17:00	Preclinical evidence of activity of palbociclib <u>A. Guerrero</u> , Valencia, ES	
17:00 - 17:20	Preclinical evidence of activity of ribociclib <u>G. Baldassarre</u> , Aviano, IT	
17:20 - 17:40	Preclinical evidence of activity of abemaciclib <u>M. Lallena</u> , Alcobendas, ES	
17:40 - 18:00	Comparison of preclinical data across CDK 4-6 <u>R. Danesi</u> , Pisa, IT	
18:00 - 18:10	Q&A	

24.03.2018



09:00 - 10:50	Interaction between CDKs, CDKI and other targets Moderation: A. Bardelli ¹ , R. Bernards ² ; ¹ Candiolo, (TO)/IT, ² Amsterdam, NL	Auditorium
09:00 - 09:20	Synthetic lethality <u>R. Bernards</u> , Amsterdam, NL	
09:20 - 09:40	RAS/RAF pathway <u>F. Di Nicolantonio</u> , Candiolo, (TO)/IT	
09:40 - 10:00	PIK3 <u>V. Serra</u> , Barcelona, ES	
10:00 - 10:20	MEK <u>O. Michielin</u> , Lausanne, CH	
10:20 - 10:40	Interaction with immune system <u>F. André</u> , Villejuif, CEDEX/FR	
10:40 - 10:50	Q&A	
11:10 - 12:40	The disappointing results of initial CDKI and their role in other disease Moderation: J. Douillard ¹ , L. Meijer ² ; ¹ Lugano - Viganello, CEDEX/CH, ² Roscoff, FR	Auditorium
11:10 - 11:35	Dinaciclib <u>C. Saura</u> , Barcelona, ES	
11:35 - 12:00	Roscovitine <u>L. Meijer</u> , Roscoff, FR	
12:00 - 12:25	CDKi in non-malignant diseases <u>L. Meijer</u> , Roscoff, FR	
12:25 - 12:40	Q&A	



13:30 - 15:00	CDK4 and CDK6 inhibitors in breast cancer Moderation: J. Cortes Castan ¹ , F. André ² ; ¹ Madrid, ES, ² Villejuif, CEDEX/FR	Auditorium
13:30 - 13:50	Palbociclib <u>J. Cortes Castan</u> , Madrid, ES	
13:50 - 14:10	Ribociclib <u>F. André</u> , Villejuif, CEDEX/FR	
14:10 - 14:30	Abemaciclib <u>A. Llombart-Cussac</u> , Lleida, ES	
14:30 - 14:50	Are all CDK 4-6 created equal? <u>G. Curigliano</u> , Milan, IT	
14:50 - 15:00	Q&A	
15:20 - 16:05	Role of CDK 4-6 inhibitors across solid tumors Moderation: G. Curigliano ¹ , F. André ² , J. Tabernero ³ , A. Bardelli ⁴ ; ¹ Milan, IT, ² Villejuif, CEDEX/FR, ³ Barcelona, ES, ⁴ Candiolo, (TO)/IT	Auditorium
16:05 - 16:20	Take-home messages and close Moderation: A. Bardelli ¹ , J. Tabernero ² ; ¹ Candiolo, (TO)/IT, ² Barcelona, ES	Auditorium